Core Viewpoint - Carter's, Inc. has adopted a limited duration stockholder rights agreement in response to the significant accumulation of its common stock by RWWM, Inc., which now holds 16.86% of the company's shares [1]. Group 1: Company Actions - The Board of Directors of Carter's, Inc. has unanimously approved the Rights Agreement to protect the interests of the company and its shareholders [1]. - The Rights Agreement is a strategic move to address the rapid accumulation of shares by RWWM, Inc. [1]. Group 2: Shareholder Dynamics - RWWM, Inc. has disclosed that it has acquired a significant stake of 16.86% in Carter's common stock [1].

Core Viewpoint - Pliant Therapeutics has adopted a limited duration stockholder rights agreement to protect stockholder interests in response to recent stock accumulations [1][2]. Group 1: Rights Agreement Details - The Rights Agreement aims to prevent any entity from gaining control of Pliant through open market accumulation without compensating all stockholders appropriately [2]. - Pliant will issue one preferred share purchase right for each outstanding share of common stock to stockholders of record on March 25, 2025 [3]. - The Rights Agreement will expire on March 11, 2026, unless terminated earlier [3]. Group 2: Exercisability and Terms - Rights become exercisable if an acquiring person obtains 10% (or 20% for certain investors) of the outstanding shares without Board approval, allowing other right holders to purchase additional shares at a 50% discount [4]. - In the event of a merger after an unapproved acquisition, right holders can purchase shares of the acquiring company at a 50% discount [4]. - The Board may redeem the rights at $0.001 per right, and existing ownership percentages prior to the Rights Agreement announcement will be grandfathered under certain conditions [5]. Group 3: Company Overview - Pliant Therapeutics is a late-stage biopharmaceutical company focused on developing therapeutics for fibrotic diseases, with its lead product candidate, bexotegrast, in development for idiopathic pulmonary fibrosis [7]. - Bexotegrast has received Fast Track and Orphan Drug Designations from the FDA and the European Medicines Agency [7]. - Pliant is also conducting Phase 1 studies for other drug candidates targeting solid tumors and muscular dystrophies [7].